

(12) UK Patent Application (19) GB (11) 2 272 155 (13) A

(43) Date of A Publication 11.05.1994

(21) Application No 9321688.5

(22) Date of Filing 21.10.1993

(30) Priority Data

(31) 9223153 (32) 05.11.1992 (33) GB

(71) Applicant(s)

John Wyeth & Brother Limited

(Incorporated in the United Kingdom)

Huntercombe Lane South, Taplow, MAIDENHEAD,
Berkshire, SL6 0PH, United Kingdom

(72) Inventor(s)

Ian Anthony Cliffe

Allan Fletcher

Alan Chapman White

(74) Agent and/or Address for Service

K J S Brown

Wyeth Laboratories, Huntercombe Lane South,
Taplow, MAIDENHEAD, Berkshire, SL6 0PH,
United Kingdom

(51) INT CL⁵

A61K 31/495

(52) UK CL (Edition M)

A5B BHA B180 B43Y B430 B47Y B470 B48Y B482 B49Y
B490 B51Y B513 B52Y B523 B54Y B541 B542 B56Y
B566 B567 B58Y B586 B59Y B596 B65Y B656 B66Y
B660 B661 B664 B666 B67Y B674 B828 B829
U1S S2418

(56) Documents Cited

None

(58) Field of Search


UK CL (Edition M) A5B BHA BJA

INT CL⁵ A61K 31/495

ONLINE DATABASE: CAS-ONLINE.


(54) Piperazine derivatives for treatment of cognitive disorders

(57) Piperazine derivatives of formula



(I)

are useful in the treatment of cognitive disorders. In formula I X is a group of



(IIa)

or



(IIb)

where n, A, R, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ have specified meanings.

PIPERAZINE DERIVATIVES

This invention relates to the use of certain piperazine derivatives in the treatment of cognitive disorders

The piperazine derivatives are those of general formula




5 and the pharmaceutically acceptable acid addition salts thereof

In formula (I)

R is hydrogen or lower alkyl,

R¹ is an aryl or nitrogen containing heteroaryl radical,

10 and X is a group of formula



or



where

15 n is one of the integers 1 or 2,

R² is hydrogen or lower alkyl,

R³ is an aryl radical or an aryl(lower)alkyl radical,

R⁴ is hydrogen or lower alkyl,

R^5 is hydrogen, an alkyl group of 1 to 8 carbon atoms, cycloalkyl of 3 to 12 carbon atoms or cycloalkyl(lower)alkyl,


5 or R^4 and R^5 together with the nitrogen atom to which they are attached represent an azetidino, pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino ring which may be optionally substituted by lower alkyl, aryl or aryl(lower)alkyl,

10 A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,

R^6 is a mono or bicyclic heteroaryl radical

15 and R^7 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula $-NR^8R^9$ [where R^9 is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R^{10} is hydrogen, lower alkyl, $-CO(lower)alkyl$, aryl, $COaryl$, aryl(lower)alkyl, cycloalkyl or cycloalkyl(lower)alkyl
20 or R^8 and R^9 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom] or a group of formula OR^{11} [where R^{11} is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl,
25 aryl(lower)alkyl, heteroaryl or heteroaryl-(lower)alkyl].

Preferred compounds of formula I are those of



or the pharmaceutically acceptable acid addition salts thereof (where n, R, R¹, R², R³, R⁴ and R⁵ are as defined above).

5 The term "lower" as used herein means that the radical referred to contains 1 to 6 carbon atoms. Preferably such radicals contain 1 to 4 carbon atoms. Examples of "lower alkyl" radicals are methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and isopentyl. Examples of cycloalkyl groups are cyclopentyl, 10 cyclohexyl and cycloheptyl. A preferred example is cyclohexyl. Cycloalkyl groups include bicyclic, tricyclic and tetracyclic groups, eg adamantyl. Preferably the cycloalkyl group contains 3 to 12 carbon atoms.

15 When used herein "aryl" means an aromatic radical having 6 to 12 carbon atoms (eg phenyl or naphthyl) which optionally may be substituted by one or more substituents. Preferred substituents are lower alkyl, lower alkoxy (eg methoxy, ethoxy, propoxy, butoxy), 20 halogen, halo(lower)alkyl (eg trifluoromethyl), nitro, nitrile, amido, (lower)alkoxycarbonyl, amino, (lower)alkylamino or di(lower)alkylamino substituents. Two substituents on the aromatic ring may be connected together to form another ring system.

25 When R¹ is an aryl radical it is preferably a phenyl radical containing a substituent in the ortho position. A preferred example of R¹ is o-(lower)alkoxyphenyl eg o-methoxyphenyl. R¹ can also be, for example a 1-naphthyl radical optionally substituted in the 2 or 7 30 positions by, for example, (lower)alkoxy.

Preferred examples of aryl(lower)alkyl are benzyl and phenethyl in which the phenyl rings may be substituted

by substituents as given above.

When used herein "nitrogen containing heteroaryl radical" means an aromatic ring containing one or more nitrogen atoms as heteroatoms (eg pyridinyl, pyrimidinyl or pyrazinyl) which may optionally be substituted by one or more lower alkyl, lower alkoxy, halogen, trifluoromethyl, amino, (lower)alkylamino or di(lower)alkylamino substituents. Preferably the heteroaryl radical is monocyclic.

When R^6 is a bicyclic heteroaryl radical both rings of the radical may contain hetero ring atoms or only one ring may contain a hetero atom or atoms. In the latter instance the radical R^6 is connected to the rest of the molecule of formula (I) via the ring containing the hetero atom(s).

Examples of the heteroaryl radical R^6 include monocyclic radicals containing one hetero atom, eg optionally substituted pyridyl (particularly 2-pyridyl), monocyclic radicals containing two hetero atoms, eg thiazolyl (particularly 2-thiazolyl) and bicyclic radicals containing one or two hetero atoms eg quinolinyl or isoquinolinyl (particularly 2-quinolinyl).

The piperazine derivatives of formula (I) and their method of preparation are disclosed, for example, in

GB 2230780A

GB 2230781A

GB 2248836A

and GB 2255337A

The compounds disclosed in GB 2230780A are described as

antidepressant and/or anxiolytic agents. The compounds disclosed in GB 2230781A, GB 2248836A and GB 2255337A are disclosed as 5-HT_{1A} antagonists useful for the treatment of CNS disorders such as anxiety, as
5 antidepressants, hypotensives and as agents for regulating the sleep/wake cycle, feeding behaviours and/or sexual function.

The preferred compounds of formula (I) are:

10 • N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide and its (S)-enantiomer

2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)-piperazinyl]]-2-phenyl]butanoyl-1H-azepine

15 (-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine

N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide

and their pharmaceutically acceptable acid addition salts.

20 The present provides in one aspect, a method of treating cognitive disorders which comprises administering to a human in need thereof an effective amount of a compound of formula (I) as defined above or a pharmaceutically acceptable acid addition salt
25 thereof. In a second aspect the invention provides the use of a compound of formula (I) as defined above or a pharmaceutically acceptable acid addition salt thereof for the manufacture of a medicament for the treatment of cognitive disorders.

The compounds are useful in the treatment of cognitive disorders such as memory deficits and dementia states. Examples of such states occur, for example, in senile dementia (eg Alzheimer's disease), brain damage caused by stroke and brain injuries, and age associated memory impairment.

In this specification the terms "treatment" and "treating" relate to the administration of the compounds to prevent the disorder as well as to treat the disorder or to alleviate the symptoms of the disorder.

The efficacy of the compounds for treating cognitive disorders can be examined in two ways. First, the influence of compounds on learning and memory in normal animals is examined by comparing the performance of compound-treated animals to vehicle treated control animals. Compounds that improve learning and memory are expected to enhance performance whereas compounds that interfere with learning and memory would be predicted to impair performance in the learning and memory tasks. Second, in an attempt to model specific diseases, learning and memory deficits can be experimentally-induced and the ability of target substances to reverse the resulting cognitive deficits examined. For example, in order induce cognitive deficits and to model the deficiency in central glutamatergic neurotransmission which occurs in Alzheimer's Disease, antagonists of glutamate receptors can be administered to animals which are then tested in a suitable behavioural procedure (e.g. the radial arm maze). In this procedure the selective 5-HT_{1A} antagonist, (-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine, has been shown to reverse the cognitive

deficits induced by the glutamate receptor antagonist, MK-801. Animals were required to learn and remember in which parts of the apparatus they could locate food rewards. The administration of MK-801 (0.1 mg/kg i.p.) significantly increased the number of errors made by the animals, compared to vehicle-pretreated controls. At doses of 0.3 and 3.0 mg/kg s.c., the 5-HT_{1A} antagonist, (-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)-piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine, significantly reversed the cognitive deficit induced by MK-801.

The compounds may be used in treating cognitive disorders in their free base form or as acid addition salts.

Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methanesulphonic, p-toluenesulphonic, oxalic and succinic acids.

The compounds of formula I contain one or more asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. The compounds can, for example, exist as racemates or optically active forms.

The compounds may be used for treating cognitive disorders in the form of pharmaceutical compositions which comprise a compound of formula I or a pharmaceutically acceptable acid addition salt thereof in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical composition. In

such a composition, the carrier is generally a solid or liquid or a mixture of a solid or liquid.

5 Solid form compositions include powders, granules, tablets, capsules (eg hard and soft gelatine capsules), suppositories and pessaries. A solid carrier can be, for example, one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression
10 aides, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary compression properties in suitable
15 proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99%, eg from 0.03 to 99%, preferably 1 to 80% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate,
20 talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

25 The term "composition" is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included.

30 Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurised compositions. The active ingredient, for example, can be dissolved or suspended in a

pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, eg cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols, eg glycerol and glycols) and their derivatives, and oils (eg fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, eg as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged composition, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquid. The unit dosage form can be, for example, a capsule or tablet itself,

or it can be the appropriate number of any such compositions in package form. The quantity of the active ingredient in unit dose of composition may be varied or adjusted from 0.5 mg or less to 750 mg or more, according to the particular need and the activity of the active ingredient.

The following Examples illustrate the invention:

Example 1Preparation of Tablets

		<u>Amount per tablet mg</u>		
5	(-)-(R)-2,3,4,5,6,7-Hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine	1	5	10
	Microcrystalline cellulose	49.25	47.25	44.75
10	Modified food corn starch	49.25	47.25	44.75
	Magnesium stearate	0.5	0.5	0.5

Tablets are prepared from bulk amounts of ingredients in the proportions given above.

15 All of the active compound, cellulose and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 1, 5 and 10
20 mg of the active ingredient per tablet.


Example 2Preparation of powder filled capsules

		<u>Amount mg</u>	
5	N-tert.butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide	10	15
	Avicel	45	
	Lactose	153	
	Starch (1500 NF)	-	117
10	Sodium starch glycollate	-	6
	Magnesium stearate	2	2

15 The formulations are prepared by admixing the ingredients in the proportions given above and filling two-part hard gelatin capsules with the required amount of the resulting mixture to give capsules containing 10 or 15 mg of the active compound.

CLAIMS

1. The use of a piperazine derivative of general formula (I)



or a pharmaceutically acceptable acid addition salt thereof

where R is hydrogen or lower alkyl,

R¹ is an aryl or nitrogen containing heteroaryl radical,

and X is a group of formula



or



where

n is one of the integers 1 or 2,

R² is hydrogen or lower alkyl,

R³ is an aryl radical or an aryl(lower)alkyl radical,

R⁴ is hydrogen or lower alkyl,

R⁵ is hydrogen, an alkyl group of 1 to 8 carbon atoms, cycloalkyl of 3 to 12 carbon atoms or cycloalkyl(lower)alkyl,

or R^4 and R^5 together with the nitrogen atom to which they are attached represent an azetidino, pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino ring which may be optionally substituted by lower alkyl, aryl or aryl(lower)alkyl,


A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,

R^6 is a mono or bicyclic heteroaryl radical

and R^7 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula $-NR^8R^9$ [where R^9 is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R^{10} is hydrogen, lower alkyl, $-CO(lower)alkyl$, aryl, $COaryl$, aryl(lower)alkyl, cycloalkyl or cycloalkyl(lower)alkyl or R^8 and R^9 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom] or a group of formula OR^{11} [where R^{11} is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl or heteroaryl-(lower)alkyl]

for the manufacture of a medicament for the treatment of cognitive disorders.

2. The use as claimed in claim 1 wherein the compound of general formula (I) has the formula



where n, R, R¹, R², R³, R⁴ and R⁵ are as defined in claim 1.

3. The use as claimed in claim 1 wherein the compound of formula (I) is

N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide or its (S)-enantiomer or

2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)-piperazinyl]]-2-phenyl]butanoyl-1H-azepine or

(-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine or

N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide.

Patents Act 1977**Examiner's report to the Comptroller under Section 17 -16-
(The Search report)**Application number
GB 9321688.5**Relevant Technical Fields**

(i) UK Cl (Ed.L) A5B (BHA, BJA)

(ii) Int Cl (Ed.5) A61K 31/495

Search Examiner
J F JENKINSDate of completion of Search
17 JANUARY 1994**Databases (see below)**

(i) UK Patent Office collections of GB, EP, WO and US patent specifications.

(ii) ONLINE DATABASE: CAS-ONLINE

Documents considered relevant
following a search in respect of
Claims :-
1 TO 3**Categories of documents**

- X:** Document indicating lack of novelty or of inventive step. **P:** Document published on or after the declared priority date but before the filing date of the present application.
- Y:** Document indicating lack of inventive step if combined with one or more other documents of the same category. **E:** Patent document published on or after, but with priority date earlier than, the filing date of the present application.
- A:** Document indicating technological background and/or state of the art. **&:** Member of the same patent family; corresponding document.

Category	Identity of document and relevant passages	Relevant to claim(s)
	NONE	

Databases: The UK Patent Office database comprises classified collections of GB, EP, WO and US patent specifications as outlined periodically in the Official Journal (Patents). The on-line databases considered for search are also listed periodically in the Official Journal (Patents).